News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

David Z. I. Cherney, MD, PhD

Articles by David Z. I. Cherney, MD, PhD

Validation of the FINE-CKD Model for Future Health Technology Assessments for Finerenone in Patients With Chronic Kidney Disease And Type 2 Diabetes

ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Aleksandra Drzewiecka, MSc,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Monika Palarczyk, MSc,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom

August 16th 2022

FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom

December 8th 2021

eAppendix: FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom

December 8th 2021

Latest Updated Articles

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access